3654 results for «415»
3654 results
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Late-breaking trials of PCR Tokyo Valves 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Procedural imaging for tricuspid valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
PCR Tokyo Valves 2026 Welcome Ceremony
14 Feb 2026 – From PCR Tokyo Valves 2026
The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.
Main vessel stenting in DK-Crush: lessons from stepwise provisional strategy
- Optimisation of side branch stenting
- How to optimally deploy the second stent
Commented by Goran Stankovic and William Wijns
Part 3 of a 3-part series. Previous episode: How to correct incomplete crush and how to prevent lack of carina coverage
Artificially synthesized optical coherence tomography images based on intravascular ultrasound-virtual histology examination of diseased coronary artery
05 May 2021
Intravascular imaging is a cornerstone of invasive management of coronary disease, requiring specialized training to interpret either IVUS or OCT. AI can facilitate interpretation by non-specialists in real time.
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation
31 Aug 2021
Following the Hot Line session of the ESC Congress 2021 presented by George Dangas (New-York, USA), Daniele Giacoppo offers us a condensed version of this study.
Author
Transcatheter aortic valve replacement in small aortic annuli: Results from the FRANCE-TAVI registry
17 Sep 2022
Mirvat Alasnag provides her take on the outcomes of small annuli sub-study from the FRANCE-TAVI Registry which included 1,195 patients. This trial was presented by Walid Ben-Ali at TCT 2022.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...
Author
Author
